OBJECTIVES: To examine the expression of the natural killer (NK) antigen CD56, and T cell receptor delta chain antigen (TCR delta), expressed on the gamma delta T cell subset, in patients with scleroderma, and to correlate levels of expression with clinical characteristics. METHODS: Peripheral blood mononuclear cells (PBMCs) from 15 patients with scleroderma and 11 controls were obtained from heparinised blood on a ficoll/hypaque gradient, stained with monoclonal antibodies, and examined by flow cytometry for expression of CD56 and TCR delta. RESULTS: Overall, the proportion of PBMCs expressing CD56 in the patient group (14.4 (SEM 2.6)%) was not significantly different from controls (8.75 (2.6)%). The greatest levels of expression were found in patients late (more than three years) in their disease course (18.1 (3.3)%) and in patients who did not express anti-Scl-70 antibodies (17.1 (3.5)%). The proportion of gamma delta T cells was significantly lower in the patient group (1.61 (0.52)% v control 2.61 (0.46)%) (p < 0.05). Patients early in their disease or with anti-Scl-70 antibodies accounted for the reduction in gamma delta T cells (0.71 (0.29)% and 0.96 (0.41)% (p < 0.01 and p < 0.05, respectively). CONCLUSIONS: This study emphasis that NK and gamma delta T cell numbers vary depending upon patient characteristics and may help explain prior contradictory reports. Decreased numbers of gamma delta T cells were seen in scleroderma patients, especially those with anti-Scl-70 antibodies and a disease duration of less than three years.
OBJECTIVES: To examine the expression of the natural killer (NK) antigen CD56, and T cell receptor delta chain antigen (TCR delta), expressed on the gamma delta T cell subset, in patients with scleroderma, and to correlate levels of expression with clinical characteristics. METHODS: Peripheral blood mononuclear cells (PBMCs) from 15 patients with scleroderma and 11 controls were obtained from heparinised blood on a ficoll/hypaque gradient, stained with monoclonal antibodies, and examined by flow cytometry for expression of CD56 and TCR delta. RESULTS: Overall, the proportion of PBMCs expressing CD56 in the patient group (14.4 (SEM 2.6)%) was not significantly different from controls (8.75 (2.6)%). The greatest levels of expression were found in patients late (more than three years) in their disease course (18.1 (3.3)%) and in patients who did not express anti-Scl-70 antibodies (17.1 (3.5)%). The proportion of gamma delta T cells was significantly lower in the patient group (1.61 (0.52)% v control 2.61 (0.46)%) (p < 0.05). Patients early in their disease or with anti-Scl-70 antibodies accounted for the reduction in gamma delta T cells (0.71 (0.29)% and 0.96 (0.41)% (p < 0.01 and p < 0.05, respectively). CONCLUSIONS: This study emphasis that NK and gamma delta T cell numbers vary depending upon patient characteristics and may help explain prior contradictory reports. Decreased numbers of gamma delta T cells were seen in sclerodermapatients, especially those with anti-Scl-70 antibodies and a disease duration of less than three years.
Authors: M Grazia Cifone; R Giacomelli; G Famularo; R Paolini; C Danese; T Napolitano; A Procopio; A M Perego; A Santoni; G Tonietti Journal: Clin Exp Immunol Date: 1990-06 Impact factor: 4.330
Authors: M Frieri; C Angadi; A Paolano; N Oster; S P Blau; S Yang; C Mele; E Hawrylko Journal: J Allergy Clin Immunol Date: 1991-04 Impact factor: 10.793
Authors: R Gerli; E Agea; A Bertotto; R Tognellini; L Flenghi; F Spinozzi; A Velardi; F Grignani Journal: J Rheumatol Date: 1991-10 Impact factor: 4.666
Authors: C M Parker; V Groh; H Band; S A Porcelli; C Morita; M Fabbi; D Glass; J L Strominger; M B Brenner Journal: J Exp Med Date: 1990-05-01 Impact factor: 14.307
Authors: R Giacomelli; P Cipriani; A Fulminis; G Barattelli; M Matucci-Cerinic; S D'Alò; G Cifone; G Tonietti Journal: Clin Exp Immunol Date: 2001-08 Impact factor: 4.330
Authors: Ana Henriques; Cláudia Silva; Mariana Santiago; Maria João Henriques; António Martinho; Hélder Trindade; José António Pereira da Silva; Bruno Silva-Santos; Artur Paiva Journal: Inflamm Res Date: 2016-08-30 Impact factor: 4.575
Authors: S Segawa; D Goto; A Iizuka; S Kaneko; M Yokosawa; Y Kondo; I Matsumoto; T Sumida Journal: Clin Exp Immunol Date: 2016-08-02 Impact factor: 4.330
Authors: L D Carbone; K J Warrington; K D Barrow; M Pugazhenthi; M A Watsky; G Somes; J Ingels; A E Postlethwaite Journal: Clin Exp Immunol Date: 2006-12 Impact factor: 4.330
Authors: Michael Gernert; Hans-Peter Tony; Eva Christina Schwaneck; Ottar Gadeholt; Matthias Fröhlich; Jan Portegys; Patrick-Pascal Strunz; Marc Schmalzing Journal: Rheumatol Int Date: 2021-10-25 Impact factor: 3.580
Authors: Ankoor Shah; Jan Storek; Rob Woolson; Ashley Pinckney; Lynnette Keyes-Elstein; Paul K Wallace; Gregory D Sempowski; Peter McSweeney; Maureen D Mayes; Leslie Crofford; M E Csuka; Kristine Phillips; Dinesh Khanna; Robert Simms; Karen Ballen; Sharon LeClercq; William St Clair; Andrew B Nixon; Richard Nash; Mark Wener; Richard Brasington; Richard Silver; Linda M Griffith; Daniel E Furst; Ellen Goldmuntz; Keith M Sullivan Journal: Rheumatology (Oxford) Date: 2022-10-06 Impact factor: 7.046
Authors: José Manuel López-Cacho; Soledad Gallardo; Manuel Posada; Miriam Aguerri; David Calzada; Teodoro Mayayo; María Luisa González-Rodríguez; Antonio María Rabasco; Carlos Lahoz; Blanca Cárdaba Journal: Biomed Res Int Date: 2014-04-10 Impact factor: 3.411